中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 35 Issue 7
Jul.  2019
Turn off MathJax
Article Contents

Establishment of Nomogram model of postoperative recurrence of primary hepatocellular carcinoma with reference to inflammatory cytokines

DOI: 10.3969/j.issn.1001-5256.2019.07.020
Research funding:

 

  • Received Date: 2019-02-28
  • Published Date: 2019-07-20
  • Objective To establish the Nomogram model of postoperative recurrence of hepatocellular carcinoma ( HCC) by collecting the data on clinical indices and inflammatory cytokines. Methods A total of 314 patients with HCC who were admitted to Wuhan Central Hospital from January 2014 to January 2016 and underwent hepatectomy for the first time were enrolled, and according to follow-up results, these patients were divided into non-recurrence group and recurrence group. General data were collected, and liver function parameters and inflammatory cytokines were measured. The chi-square test was used for comparison of categorical data between two groups, and the Mann-Whitney U test was used for comparison of ranked data between two groups. The receiver operating characteristic ( ROC) curve was used to obtain the optimal cut-off values of continuous data. The multivariate Cox proportional hazards model was used to investigate the independent risk factors for recurrence. The Nomogram model was established according to the results of the multivariate Cox proportional hazards model and was validated by internal data, and the consistency index ( C-index) was calculated. Results The follow-up time ranged from1 month to 40 months, with a median follow-up time of 13 months. Of all patients, 140 had no recurrence, and 174 experienced recurrence. The median recurrence-free survival time was 19 months, and the half-, 1-, and 2-year recurrence-free survival rates were68. 2%, 57. 3%, and 45. 9%, respectively. There were significant differences between the two groups in age, maximum tumor diameter, body mass index ( BMI) , interleukin-2, interleukin-6, interleukin-8, interleukin-17 ( IL-17) , neutrophil-lymphocyte ratio, tumor necrosis factor α ( TNF α) , C-reactive protein, alanine aminotransferase ( ALT) , aspartate aminotransferase, and total bilirubin ( TBil) ( all P < 0. 05) . The Cox proportional hazards model showed that age > 63 years ( hazard ratio[HR]= 2. 391, P < 0. 05) , maximum tumor diameter > 6 cm ( HR = 1. 851, P < 0. 05) , BMI > 27. 17 kg/m2 ( HR = 1. 546, P < 0. 05) , IL-17 > 10. 8 pg/m L ( HR = 1. 556, P <0. 05) , TNF α > 11. 8 ng/L ( HR = 1. 562, P < 0. 05) , ALT > 42 U/L ( HR = 1. 624, P < 0. 05) , and TBil > 15. 6 μmol/L ( HR = 1. 534, P < 0. 05) were independent risk factors for postoperative recurrence in patients with HCC. Validation by internal data showed a C-index of0. 724 ( 95% confidence interval: 0. 668-0. 824) . Conclusion The Nomogram model established in this study can accurately predict the recurrence of HCC patients after first-time hepatectomy, but more clinical studies are needed to confirm this result.

     

  • loading
  • [1]FERLAY J, SOERJOMATARAM I, DIKSHIT R, et al.Cancer incidence and mortality worldwide:Sources, methods and major patterns in GLOBOCAN 2012[J].Int J Cancer, 2015, 136 (5) :359-386.
    [2] YAMASAKI S, HASEGAWA H, MAKUUCHI M, et al.Choice of treatments for small hepatocellular carcinoma:Hepatectomy, embolization or ethanol injection[J].J Gastroenterol, 2010, 6 (4) :408-413.
    [3] POON RP, FAN ST, NG OL, et al.Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma[J].Cancer, 2000, 89 (3) :500-507.
    [4]POON RP, FAN ST, NG OL, et al.Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function:Implications for a strategy of salvage transplantation[J].Ann Surg, 2002, 235 (3) :373-382.
    [5]GRIVENNIKOV SI, GRETEN FR, KARIN M.Immunity, inflammation, and cancer[J].Mol Biol Cell, 2010, 140 (6) :833-899.
    [6] Liver Surgery Group, Surgical Society of Chinese Medical Association.Expert consensus on selection of surgical treatments for hepatocellular carcinoma (2016 3rd edition) [J].Chin JDig Surg, 2017, 16 (2) :113-115. (in Chinese) 中华医学会外科学分会肝脏外科学组.肝细胞癌外科治疗方法的选择专家共识 (2016年第3次修订) [J].中华消化外科杂志, 2017, 16 (2) :113-115.
    [7]YANG Z, WANG JL, SHANG RZ, et al.Correlation between preoperative serum alpha-fetoprotein (AFP) level and early recurrence of patients the hepatocellular carcinoma after partial hepatectomy[J].Chin J Hepatobiliary Surg, 2018, 24 (3) :179-183. (in Chinese) 杨针, 汪建林, 尚润泽, 等.术前血清甲胎蛋白水平与肝细胞癌术后患者早期复发的相关性分析[J].中华肝胆外科杂志, 2018, 24 (3) :179-183.
    [8] JUNG SM, KIM JM, CHOI GS, et al.Characteristics of early recurrence after curative liver resection for solitary hepatocellular carcinoma[J].J Gastrointest Surg, 2019, 23 (2) :304-311.
    [9]TANAKA S, LIMURO Y, HIRANO T, et al.Safety of hepatic resection for hepatocellular carcinoma in obese patients with cirrhosis[J].Surg Today, 2013, 43 (11) :1290-1297.
    [10] NISHIKAWA H, OSAKI Y, TAKEDA H, et al.Effect of body mass index on survival after curative therapy for non-B nonC hepatocellular carcinoma[J].Chin J Cancer, 2013, 22 (2) :173-181.
    [11]TIAN J, MENG QH, LIANG QY, et al.Research progress in the associations of metabolic diseases and therapeutic drugs with hepatocellular carcinomas[J].Chin J Clin Pharmacol Ther, 2019, 24 (1) :103-110. (in Chinese) 田婧, 蒙秋华, 梁秋云, 等.代谢性疾病及治疗药物与肝癌的相关性研究进展[J].中国临床药理学与治疗学, 2019, 24 (1) :103-110.
    [12] LORINCZ MA.Molecular links between obesity and breast cancer[J].Endocr Relat Cancer, 2006, 13 (2) :279-292.
    [13]WANG XJ, YUAN SL, LU Q, et al.Potential involvement of leptin in carcinogenesis of hepatocellular carcinoma[J].World J Gastroenterol, 2004, 10 (17) :2478-2481.
    [14]DENG WW, ZHU WM, YI C, et al.Association of serum interleukin-17 level with early recurrence and prognosis after radical surgery in hepatocellular carcinoma patients with differentlevels of alpha-fetoprotein[J].J Clin Hepatol, 2018, 34 (2) :298-302. (in Chinese) 邓伟伟, 朱文明, 易超, 等.不同AFP水平下血清IL-1与肝癌根治术后早期复发和预后的关系[J].临床肝胆病杂志, 2018, 34 (2) :298-302.
    [15]TU JF, PAN HY, YING XH, et al.Mast cells comprise the major of interleukin 17-producing cells and predict a poor prognosis in hepatocellular carcinoma[J].Medicine (Baltimore) , 2016, 95 (13) :e3220.
    [16]AZZAZENE D, AL THAWADI H, AL FARSI H, et al.Plasma endothelial protein C receptor influences innate immune response in ovarian cancer by decreasing the population of natural killer and TH17 helper cells[J].Int J Oncol, 2013, 43 (4) :1011-1018.
    [17]ZHAGN JH, ZHENG C, ZHOU ZH, et al.Research progress of relationship the between immune cells and hepatocellular carcinoma[J].China Med Herald, 2018, 15 (36) :24-27. (in Chinese) 张景豪, 郑超, 周振华, 等.免疫细胞与肝细胞癌关系的研究进展[J].中国医药导报, 2018, 15 (36) :24-27.
    [18] FRANCK H, ABBY G, ERIK TO, et al.Interleukin-17 and type 17 helper T cells in cancer management and research[J].Immunotargets Ther, 2014, 10 (3) :39-54.
    [19] HU Z, LUO D, WANG D, et al.IL-17 activates the IL-6/STAT3 signal pathway in the proliferation of hepatitis B virusrelated hepatocellular carcinoma[J].Cell Physiol Biochem, 2017, 43 (6) :2379-2390.
    [20]BALACHANDRAN VP, GONEN M, SMITH JJ, et al.Nomograms in oncology:More than meets the eye[J].Lancet Oncol, 2015, 16 (4) :173-180.
    [21]TAN W, LUO X, LI W, et al.TNF-αis a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma[J].EBio Medicine, 2018, 40:446-456.
    [22]AYUBI E, SAFIRI S.Nomogram predicting long-term survival after the diagnosis of intrahepatic recurrence of hepatocellular carcinoma following an initial liver resection:Methodological issues[J].Int J Clin Oncol, 2017, 22 (4) :715-725.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (1408) PDF downloads(271) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return